In seeking to expand affordable access to PD1/PD-L1 inhibitors for advanced NSCLC, policymakers should work with the stakeholders to negotiate lower prices, implement measures to improve spending efficiency (e.g., optimizing dose and treatment duration) and enhance health system capacity, including ensuring appropriate use and its readiness for introducing more affordable biosimilar medicines. This evidence concerns the gene CD274 and non-small cell lung carcinoma.